Simplifying the Shang Ring Technique for Circumcision of Men and Boys
Launched by ENGENDERHEALTH · Mar 10, 2015
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
The study, to be conducted in two phases, will examine procedural and clinical outcomes, as well as participant and provider acceptability, of adaptations of the Shang Ring technique for male circumcision that would simplify its use and increase its acceptability.
* Phase I will be non-comparative for exploration of the no-flip technique for Shang Ring circumcision (i.e. all participants will be circumcised using the no-flip Shang Ring technique). Historical data from standard Shang Ring circumcisions conducted in Africa (Kenya, Uganda and Zambia) will be used as the comparison group. Men ...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Aged 10 years and older;
- • Uncircumcised upon clinical examination;
- • In good general health;
- • Free of genital ulcerations or other visible signs of sexually transmitted infections upon clinical examination;
- • Participant and parent or legally acceptable representative (LAR) as applicable must be able to understand study procedures and requirements of study participation;
- • Freely consents to participate in the study and signs a written informed consent form if 18 years of age or greater
- • Accompanied by the parent/LAR, who freely consents and signs an informed consent form for participation of the child into the study for participants less than 18 years old;
- • Assent from participant less than 18 years old who understand study procedure;
- • Participant must agree to return to the study site for the full schedule of follow-up visits after his circumcision (or as appropriate the Parent or LAR must agree to bring the participant);
- • Participant and parent/LAR as appropriate must agree to provide the study staff with an address, phone number, or other locator information while participating in the research study.
- Exclusion Criteria:
- • Has a known allergy or sensitivity to lidocaine or other local anesthesia;
- • Takes a medication that would be a contraindication for elective surgery, such as an anticoagulant or steroid;
- • Has known bleeding/clotting disorder (e.g. hemophilia);
- • Has any congenital genitourinary abnormality;
- • Has an active genital infection, anatomic abnormality or other condition (e.g. diabetes or sickle cell anemia), which in the opinion of the surgeon, prevents the man from undergoing a circumcision as part of this study; or,
- • Is currently participating in another biomedical research study.
Trial Officials
Mark A Barone, DVM, MS
Principal Investigator
EngenderHealth
About Engenderhealth
EngenderHealth is a leading global nonprofit organization dedicated to improving sexual and reproductive health and rights worldwide. With a focus on innovative solutions and evidence-based practices, EngenderHealth partners with governments, communities, and health systems to enhance access to quality healthcare services. The organization emphasizes the importance of gender equity and empowerment in its initiatives, working tirelessly to develop and implement programs that address critical health issues, including family planning, maternal health, and the prevention of sexually transmitted infections. Through its commitment to research and clinical trials, EngenderHealth aims to advance knowledge and improve health outcomes for individuals and communities in diverse settings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Homa Bay, Homa Bay County, Kenya
Vipingo, Kilifi County, Kenya
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials